WO2000057837A3 - Compositions and methods for effecting the levels of cholesterol - Google Patents

Compositions and methods for effecting the levels of cholesterol Download PDF

Info

Publication number
WO2000057837A3
WO2000057837A3 PCT/US2000/007870 US0007870W WO0057837A3 WO 2000057837 A3 WO2000057837 A3 WO 2000057837A3 US 0007870 W US0007870 W US 0007870W WO 0057837 A3 WO0057837 A3 WO 0057837A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol
methods
compositions
levels
effecting
Prior art date
Application number
PCT/US2000/007870
Other languages
French (fr)
Other versions
WO2000057837A9 (en
WO2000057837A8 (en
WO2000057837A2 (en
Inventor
Michael Jaye
Kevin J Lynch
Dilip V Amin
Kim-Anh Thi Doan
Dawn Marchadier
Cyrille Maugeais
Daniel J Rader
John A Krawiec
Victoria J South
Original Assignee
Aventis Pharm Prod Inc
Univ Pennsylvania
Michael Jaye
Kevin J Lynch
Dilip V Amin
Doan Kim Anh Thi
Dawn Marchadier
Cyrille Maugeais
Daniel J Rader
John A Krawiec
Victoria J South
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Priority to JP2000607588A priority Critical patent/JP2002540127A/en
Priority to CA2363486A priority patent/CA2363486C/en
Priority to IL14552600A priority patent/IL145526A0/en
Priority to NZ51435000A priority patent/NZ514350A/en
Application filed by Aventis Pharm Prod Inc, Univ Pennsylvania, Michael Jaye, Kevin J Lynch, Dilip V Amin, Doan Kim Anh Thi, Dawn Marchadier, Cyrille Maugeais, Daniel J Rader, John A Krawiec, Victoria J South filed Critical Aventis Pharm Prod Inc
Priority to BR0009333-5A priority patent/BR0009333A/en
Priority to AU39187/00A priority patent/AU776684B2/en
Priority to MXPA01009727A priority patent/MXPA01009727A/en
Priority to EP00918362A priority patent/EP1171078A4/en
Publication of WO2000057837A2 publication Critical patent/WO2000057837A2/en
Publication of WO2000057837A3 publication Critical patent/WO2000057837A3/en
Priority to IL145526A priority patent/IL145526A/en
Priority to NO20014657A priority patent/NO331779B1/en
Publication of WO2000057837A8 publication Critical patent/WO2000057837A8/en
Publication of WO2000057837A9 publication Critical patent/WO2000057837A9/en
Priority to HK02104818.0A priority patent/HK1043309A1/en
Priority to NO20100214A priority patent/NO331784B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the tryacylglycerol lipase family or which effect the enzymatic activity of the enzyme.
PCT/US2000/007870 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol WO2000057837A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL14552600A IL145526A0 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
MXPA01009727A MXPA01009727A (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol.
EP00918362A EP1171078A4 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
NZ51435000A NZ514350A (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol
CA2363486A CA2363486C (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
BR0009333-5A BR0009333A (en) 1999-03-26 2000-03-24 Composition to reduce lipg gene expulsion and the enzymatic activity of the lipg polypeptide, to inhibit the enzymatic activity of the lipg polypeptide, to increase the level and enzymatic activity of the lipg polypeptide in a patient and methods to increase the cholesterol level of high density lipoprotein and apolipoprotein ai, to reduce the level of very low density lipoprotein cholesterol and ldl cholesterol and vldl cholesterol in a patient, to diagnose a predisposition to low levels of hdl cholesterol and apolipoprotein ai, and to determine whether a test compound can inhibit the enzymatic reaction between lipg polypeptide and hdl cholesterol and apolipoprotein ai and can increase the enzymatic reaction between lipg polypeptide and vldl and vdl cholesterol
AU39187/00A AU776684B2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
JP2000607588A JP2002540127A (en) 1999-03-26 2000-03-24 Compositions and methods for providing cholesterol levels
IL145526A IL145526A (en) 1999-03-26 2001-09-20 Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl
NO20014657A NO331779B1 (en) 1999-03-26 2001-09-25 Methods for determining whether a test compound can inhibit the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein A1 or promote the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol or LDL cholesterol
HK02104818.0A HK1043309A1 (en) 1999-03-26 2002-06-28 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
NO20100214A NO331784B1 (en) 1999-03-26 2010-02-11 Use of a ribozyme for the preparation of a composition capable of reducing the enzymatic activity of LIPG in a patient.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/277,401 1999-03-26
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol

Publications (4)

Publication Number Publication Date
WO2000057837A2 WO2000057837A2 (en) 2000-10-05
WO2000057837A3 true WO2000057837A3 (en) 2001-01-25
WO2000057837A8 WO2000057837A8 (en) 2001-09-27
WO2000057837A9 WO2000057837A9 (en) 2001-10-18

Family

ID=23060703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007870 WO2000057837A2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Country Status (13)

Country Link
EP (1) EP1171078A4 (en)
JP (1) JP2002540127A (en)
KR (2) KR100887164B1 (en)
AU (1) AU776684B2 (en)
BR (1) BR0009333A (en)
CA (1) CA2363486C (en)
HK (1) HK1043309A1 (en)
IL (2) IL145526A0 (en)
MX (1) MXPA01009727A (en)
NO (2) NO331779B1 (en)
NZ (2) NZ531180A (en)
WO (1) WO2000057837A2 (en)
ZA (1) ZA200107598B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
ES2629630T3 (en) 2008-12-04 2017-08-11 Curna, Inc. Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
ES2762610T3 (en) 2009-02-12 2020-05-25 Curna Inc Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF
MX2011009751A (en) 2009-03-16 2011-09-29 Opko Curna Llc Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
JP6250930B2 (en) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド Treatment of TTP-related diseases by suppression of natural antisense transcripts against tristetraproline (TTP)
CN102459596B (en) 2009-05-06 2016-09-07 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
KR101742334B1 (en) 2009-05-08 2017-06-01 큐알엔에이, 인크. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
CN102575251B (en) 2009-05-18 2018-12-04 库尔纳公司 The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
CN103221541B (en) 2009-05-28 2017-03-01 库尔纳公司 Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
KR101702689B1 (en) 2009-06-16 2017-02-06 큐알엔에이, 인크. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US9234199B2 (en) 2009-08-05 2016-01-12 Curna, Inc. Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
EP2464731B1 (en) 2009-08-11 2016-10-05 CuRNA, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
CN102482671B (en) 2009-08-25 2017-12-01 库尔纳公司 IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP)
EP2480669B1 (en) 2009-09-25 2017-11-08 CuRNA, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
CA2782373C (en) 2009-12-23 2019-03-26 Opko Curna, Llc Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
ES2585829T3 (en) 2009-12-29 2016-10-10 Curna, Inc. Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63
WO2011090740A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
US20120289583A1 (en) 2009-12-31 2012-11-15 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
KR101878501B1 (en) 2010-01-04 2018-08-07 큐알엔에이, 인크. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
EP2521785B1 (en) 2010-01-06 2022-03-09 CuRNA, Inc. Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
CN102782135A (en) 2010-01-25 2012-11-14 库尔纳公司 Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
CN102844435B (en) 2010-02-22 2017-05-10 库尔纳公司 Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
ES2657969T3 (en) 2010-04-02 2018-03-07 Curna, Inc. Treatment of diseases related to Colony Stimulating Factor 3 (CSF3) by inhibition of the natural antisense transcript to CSF3
RU2610661C2 (en) 2010-04-09 2017-02-14 Курна, Инк. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CN107988228B (en) 2010-05-03 2022-01-25 库尔纳公司 Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT)
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
CA2799596C (en) 2010-05-26 2020-09-22 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
KR102008708B1 (en) 2010-06-23 2019-08-08 큐알엔에이, 인크. Treatment of sodium channel voltage-gated, alpha subunit (scna) related diseases by inhibition of natural abtisense transcript to scna
CN103068982B (en) 2010-07-14 2017-06-09 库尔纳公司 DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG)
EP2625274B1 (en) 2010-10-06 2017-07-19 CuRNA, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
CN103459599B (en) 2010-11-23 2017-06-16 库尔纳公司 NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG
JP6188686B2 (en) 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN)
CA2847811C (en) 2011-09-06 2019-10-22 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN102628060A (en) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 Production method of low-fat milk
US9695462B2 (en) 2012-11-05 2017-07-04 Shionogi & Co., Ltd. Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity
KR102034478B1 (en) * 2013-03-14 2019-10-21 시오노기 앤드 컴파니, 리미티드 Monoclonal antibody inhibiting enzymatic activity of endothelial lipase
TWI734410B (en) 2014-09-11 2021-07-21 日商塩野義製藥股份有限公司 Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
BR112023015303A2 (en) 2021-02-01 2023-11-14 Regenxbio Inc METHOD TO TREAT CLN2 DISEASE DUE TO TPP1 DEFICIENCY IN A SUBJECT
WO2023008337A1 (en) * 2021-07-26 2023-02-02 ピューロテックバイオ株式会社 Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707638A4 (en) * 1992-12-04 1998-05-20 Innovir Lab Inc Regulatable nucleic acid therapeutic and methods of use thereof
CZ299055B6 (en) * 1996-12-06 2008-04-09 Aventis Pharmaceuticals Inc. Isolated polypeptide encoded by a lipase like gene, composition having phospholipase activity, pharmaceutical composition, isolated immunizing peptide and nucleic acid, biologically compatible solution, vector, recombinant cell, formulation useable f
AU1941899A (en) * 1997-12-19 1999-07-12 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAYE M. ET AL.: "A Novel endothelial-derived lipase that modulates HDL metabolism", vol. 21, April 1999 (1999-04-01), pages 424 - 428, XP002932771 *
TSUKAMOTO K. ET AL.: "Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus", vol. 38, 1997, pages 1869 - 1876, XP002932770 *

Also Published As

Publication number Publication date
JP2002540127A (en) 2002-11-26
CA2363486C (en) 2012-12-18
AU776684B2 (en) 2004-09-16
NZ531180A (en) 2005-06-24
KR100887164B1 (en) 2009-03-10
WO2000057837A9 (en) 2001-10-18
IL145526A (en) 2010-11-30
NO20014657L (en) 2001-11-21
NO20100214L (en) 2001-11-21
WO2000057837A8 (en) 2001-09-27
NO331779B1 (en) 2012-03-26
EP1171078A2 (en) 2002-01-16
KR20020029651A (en) 2002-04-19
KR20050044812A (en) 2005-05-12
MXPA01009727A (en) 2002-07-22
NO331784B1 (en) 2012-03-26
NO20014657D0 (en) 2001-09-25
HK1043309A1 (en) 2002-09-13
BR0009333A (en) 2002-01-08
AU3918700A (en) 2000-10-16
IL145526A0 (en) 2002-06-30
CA2363486A1 (en) 2000-10-05
NZ514350A (en) 2004-12-24
WO2000057837A2 (en) 2000-10-05
ZA200107598B (en) 2003-05-28
EP1171078A4 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
WO2000057837A3 (en) Compositions and methods for effecting the levels of cholesterol
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO2007053619A3 (en) A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
MX9702204A (en) RIBOZYME TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF PLASMA LIPOPROTEIN (a) [Lp(a)] BY INHIBITING APOLIPOPROTEIN (a) [APO(a)].
DK0738512T3 (en) Method of preventing another heart attack using an HMG coenzyme A reductase inhibitor
AU8757898A (en) Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
WO2001015676A3 (en) Compositions and methods for modulating hdl cholesterol and triglyceride levels
WO2001049255A3 (en) Methods and compositions for inhibiting adhesion by microorganisms
AU2003278816A1 (en) ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
AU2002242633A1 (en) Fermentation process including the use of enzymes
WO2005096704A3 (en) Cholesterol lowering composition
IL159368A0 (en) Method of modifying enzyme and oxidoreductase variant
WO2005004814A3 (en) Sirt1 and genetic disorders
WO2002060972A3 (en) Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
AU6949200A (en) Human hydrolytic enzymes
AU2003207426A1 (en) Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
DE69724613D1 (en) Antimicrobial agents against eukaryotic microorganisms and methods for suppressing the growth of eukaryotic microorganisms using such agents
AU2002359403A1 (en) METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER
DE60029624D1 (en) HOMOLOGOUS ENZYMES OF HUMAN HEPARANASE AND ALTERNATIVE SPLICE FORMAT THEREOF
WO2003056897A3 (en) Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
AU2002316148A1 (en) Lipase catalyzed esterification, transesterification, and hydrolysis of arylthiols and aryl-thioesters
EP0949330A3 (en) Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures
AU5530800A (en) Method and composition for enhancing the activity of an enzyme
WO2002091926A3 (en) Inhibitors of dna methyltransferase isoforms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2363486

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 514350

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2000 607588

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009727

Country of ref document: MX

Ref document number: 39187/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020017012300

Country of ref document: KR

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2000918362

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/28-28/28, DRAWINGS, REPLACED BY NEW PAGES 1/30-30/30; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2000918362

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017012300

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 39187/00

Country of ref document: AU